Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Safety and Efficacy Trial of LJP 394 in Systemic Lupus Erythematosus (SLE) Patients With a History of Renal Disease

NCT00035308 is registered in ClinicalTrials.gov with La Jolla Pharmaceutical Company as lead sponsor.

NCT NCT00035308
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00035308 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Safety and Efficacy Trial of LJP 394 in Systemic Lupus Erythematosus (SLE) Patients With a History of Renal Disease
Lead sponsor
La Jolla Pharmaceutical Company
Phase
Phase 3
Overall status
Completed
Start date
Not reported
Completion date
December 31, 2002
Enrollment
330
Sites
82

Conditions

As the registry lists them; a condition with its own page is linked.

autoimmune diseases, immunologic diseases, lupus glomerulonephritis, lupus nephritis, systemic lupus erythematosus